Non-Surgical Rhinoplasty: Assessment, Anatomy, & Technique

Indications and Suitability

Non-surgical rhinoplasty uses injectable treatment, usually hyaluronic acid filler, to alter nasal contour by adding volume. It is a camouflage procedure, not a structural rhinoplasty.

Patient Selection

Offer treatment only when the patient’s goal is contour refinement rather than major architectural change.

• Minor contour issues: consider HA filler for dorsal irregularity, mild asymmetry, concavity, or under-projection ².
• Tip and dorsum: selected tip projection and dorsal morphology concerns may be appropriate ¹.
• Post-rhinoplasty defects: filler may help selected imperfections and may avoid revision surgery in some patients ³.
• Post-reconstruction cases: consider only when oncological surgery is remote, stable, and further surgery is declined or unsuitable ⁴.

Treatment Boundaries

Decline or redirect treatment when filler cannot safely solve the dominant anatomical problem.

• Severe deformity: large humps, marked deviation, or significant tip rotation should prompt surgical assessment ².
• Major structural change: filler cannot reduce bone, narrow the nose, straighten the septum, or improve airway obstruction.
• Over-augmentation risk: a bulky nose, thick envelope, or wide dorsum may look worse after additive treatment.
• Unsuitable expectations: defer when the patient wants a smaller nose, perfect symmetry, or a surgical result without surgery.

Contraindications

Screen actively for medical, anatomical, and psychological factors that make treatment unsafe or inappropriate.

• Medical risks: assess bleeding risk, antithrombotic therapy, pregnancy or nursing, and lidocaine or HA sensitivity ⁵.
• Tissue disease: connective-tissue disease or impaired vascular reserve should lower the threshold to defer ⁵.
• Prior treatment: previous filler, threads, surgery, or reconstruction changes anatomy and vascular risk.
• Body image concern: suspected dysmorphic syndrome should prompt deferral and careful referral rather than injection ⁵.

Applied Anatomy

The nose is unforgiving because small filler volumes can alter contour and small vascular events can be catastrophic. Anatomy must guide both aesthetic planning and stopping rules.

Nasal Layers

Choose the injection plane deliberately rather than placing filler wherever the contour deficit appears.

• Layer sequence: plan from skin through superficial fat, fibromuscular layer, deep fat, perichondrium or periosteum, then cartilage or bone ⁵.
• Preferred plane: filler plans commonly target the deep fat layer over perichondrium or periosteum ⁶.
• Thin skin: superficial placement risks visibility, Tyndall effect, nodularity, and vascular encounter.
• Thick skin: contour change may require more volume, increasing over-augmentation and compression risk.

Blood Supply

Assume clinically relevant vessels may be present even in apparently safe midline sites.

• Superficial vessels: nasal vessels commonly run between superficial fat and fibromuscular layers, making plane selection central to safety ¹.
• Tip risk: Doppler ultrasound found a midline vessel in 18 of 21 nasal tips, with half located deep ⁷.
• Radix risk: midline radix vessels were found less often in that sample and were superficial, but this does not make the radix risk-free ⁷.
• Anastomoses: dorsal nasal, angular, lateral nasal, and ophthalmic-linked pathways explain skin and visual complications.

Danger Zones

Treat the nasal triangle as a high-consequence filler zone, not a routine facial contour area.

• Nasal triangle: the nose and adjacent nasal triangle are facial vascular danger zones during filler planning ⁸.
• Tip and alae: small-calibre vascular territories are vulnerable to embolic and compressive compromise.
• Dorsum: midline treatment reduces but does not eliminate vascular risk.
• Glabella-radix link: retrograde arterial flow can connect filler embolus to ocular circulation.

Keystone Area

Be cautious with post-rhinoplasty dorsal irregularities because thin skin over mixed bone-cartilage support exposes small planning errors.

• Complex overlap: the keystone area contains bone-cartilage overlap under thin skin, affecting filler camouflage planning ³.
• Defect types: inverted-V deformity, saddle change, or small asymmetry need careful counselling because correction is challenging ³.
• Camouflage limit: filler may hide shadowing but cannot rebuild unstable support.
• Scarred envelope: prior surgery may tether skin and alter vascular pathways.

Nasal Subunits

Match filler placement to the visible subunit deformity while protecting subunit boundaries.

• Radix: modest augmentation can change the dorsal starting point and nasofrontal angle.
• Dorsum: linear contour smoothing must avoid widening or dorsal overfill.
• Tip: projection change needs very small volumes and high vascular caution.
• Alar and sidewall: avoid casual injection; asymmetry may be structural, scarred, or airway-related.

Assessment and Planning

Planning prevents two common errors: offering filler for a surgical problem and injecting a nose with unrecognised vascular or scar risk. The decision should be made before the syringe is opened.

History

Use the history to identify altered anatomy, contraindications, and dissatisfaction risk.

• Prior rhinoplasty: record open or closed surgery, grafts, implants, complications, and revision plans.
• Previous filler: ask product, date, volume, response, dissolution, nodules, infection, or vascular symptoms.
• Medical risk: document bleeding tendency, anticoagulants, autoimmune disease, pregnancy, allergy, and wound-healing concerns.
• Satisfaction risk: pre-procedural ROE assessment may help identify psychological or satisfaction-risk concerns ⁹.

Examination

Analyse whether the visible concern is correctable by adding small, well-placed volume.

• Frontal view: assess deviation, asymmetry, dorsal aesthetic lines, tip position, and alar contour.
• Profile view: assess radix height, dorsal hump, supratip break, tip projection, and nasolabial angle.
• Skin envelope: thin skin shows filler; thick skin hides correction and encourages overfilling.
• Dynamic features: depressor septi activity or facial animation may mimic structural tip descent.

Deformity Mapping

Plan target zones and volume conservatively before treatment begins.

• Treatment zones: planning may include the nasal root, dorsum, tip, wings, and subnasal region ¹.
• Volume discipline: most reviewed protocols used less than 1 mL per procedure, supporting conservative planning ¹¹.
• Staging: stop early if the nose looks better; further treatment can be staged.
• No reduction: a hump is camouflaged by filling around it, not removed.

Imaging and Documentation

Photograph and document enough to judge symmetry, consent, and later complications.

• Baseline photography: obtain frontal, oblique, lateral, basal, and smiling views.
• ROE questionnaire: ROE can structure subjective assessment before and after NSR ⁹.
• 3D imaging: 3D surface imaging may support objective outcome assessment, but is not a validated standard for NSR planning ¹².
• Ultrasound adjunct: pre-procedural or procedural ultrasound may improve safety by tailoring placement to vascular pattern ⁷.

Product and Technique Selection

Technique selection is not a matter of injector preference alone. It should follow anatomy, target deformity, product behaviour, and reversibility.

Filler Choice

Prefer hyaluronic acid because nasal treatment needs reversibility, precision, and conservative volume control.

• HA dominance: after prior rhinoplasty, HA was the most frequently reported filler, used in 1,373 of 2,048 patients ³.
• Product selection: one review found Juvéderm Ultra commonly used, but product choice should still follow anatomy and technique ¹⁴.
• Permanent fillers: avoid routine permanent filler because complications and later surgery are harder to manage.
• Regulatory consent: counsel that nasal HA filler use is off-label in the United States ¹⁰.

Injection Instrument

Use the instrument that gives the safest controlled placement for the planned site.

• Needle use: best for precise microbolus placement onto bone or cartilage under direct control.
• Cannula use: useful for selected linear contouring but still requires vascular caution and a defined plane.
• Access choice: minimise entry points and avoid repeated traumatic passes through scarred tissue.
• False reassurance: cannula, aspiration, and midline placement reduce risk but do not abolish it.

Injection Pattern

Match bolus, threading, and sequence to the contour problem rather than filling every nasal subunit.

• Microbolus: use for focal radix, dorsal, or tip support on a firm deep plane.
• Linear threading: use sparingly for dorsal smoothing where a continuous contour is required.
• Sequencing: structured HA protocols may inject tip, then columella, then radix and dorsum ⁵.
• Site planning: one described approach plans tip, columellar base, dorsum including the supratip, and radix sites ¹³.

Selection Framework

Let the dominant deformity decide the product, plane, and endpoint.

• Decision anchor: choose the minimum intervention that produces a visible, safe improvement.
• Safety anchor: stop when contour is improved, not when the planned syringe is empty.

Adjunct Options

Keep threads and toxin secondary to the main filler decision unless they specifically match the problem.

• Threads: may be considered for selected dorsal or tip support, but extrusion, infection, and revision issues matter.
• Botulinum toxin: may help a dynamic depressor component but will not correct bony or cartilaginous deformity ⁶.
• Technique caution: critical-site and multiplane approaches require caution because higher complication rates were reported in one review ¹.

Procedural Principles

The procedure fails when additive treatment is used to chase a reductive goal, or when vascular warning signs are ignored. Set limits before injecting.

Consent and Time-Out

Confirm the plan, product, dose limit, vascular rescue kit, and stopping rules before skin preparation.

• Consent focus: include asymmetry, overcorrection, nodules, infection, vascular compromise, necrosis, and visual symptoms.
• Additive anatomy: filler rhinoplasty changes shape by adding volume, so over-augmentation must be planned against ¹³.
• Emergency readiness: confirm hyaluronidase availability, contact pathways, and escalation arrangements.
• Photography: review baseline images and mark target points with the patient upright.

Asepsis and Marking

Mark the aesthetic endpoint and clean the field as for a high-consequence injectable procedure.

• Marking: identify radix, dorsal irregularity, supratip, tip point, columella, and danger areas.
• Skin preparation: remove make-up and use antisepsis before injection.
• Anaesthesia: local anaesthetic with epinephrine may be used in preparation because vasoconstriction may reduce embolism risk ¹.
• Minimal trauma: avoid repeated passes, especially in scarred or previously operated noses.

Injection Technique

Inject slowly, deeply, and centrally, then reassess after every small aliquot.

1. Set the endpoint: Decide the smallest correction that will satisfy the planned contour change.

• Volume control: use micro-aliquots and reassess from frontal and profile views.
• Pitfall: do not use filler to chase nasal narrowing.

2. Use the intended plane: Place product in the midline supraperiosteal or supraperichondrial plane where appropriate.

• Safety principle: supraperiosteal, above-cartilage, or midline injection is described to limit vascular damage ².
• Pitfall: superficial placement increases visibility and vascular risk.

3. Check perfusion: Observe pain, blanching, livedo, capillary refill, and patient-reported visual symptoms.

• Capillary refill: one protocol checked for refill under 2 seconds ⁵.
• Pitfall: aspiration is only a checkpoint, not proof of safety, although it is described to reduce intravascular occlusion risk ².

Injection Sequence

Establish tip position only when indicated, then adjust the dorsum to match the new contour.

• Ascending logic: in the ascending approach, tip projection and rotation are set first, then the dorsum is adjusted ¹³.
• Midline discipline: top-to-bottom and bottom-up midline supraperiosteal approaches are recognised options ¹.
• Danger-zone awareness: technique should prioritise facial vascular danger zones and appropriate filler choice ⁸.
• Stopping rule: stop immediately for severe pain, blanching, dusky colour, livedo, or visual symptoms.

Complications

Nasal filler complications are high-stakes because the treatment is elective and the vascular territory is unforgiving. Minor swelling is common; pain, colour change, or visual symptoms are not minor.

Vascular Compromise

Treat severe pain, blanching, livedo, delayed refill, dusky skin, or visual symptoms as vascular compromise until proven otherwise.

• Prior rhinoplasty: previous rhinoplasty should be treated as a risk factor for vascular compromise and skin necrosis ³.
• Severe risks: consent should include blindness, cerebral infarction, skin necrosis, and motor nerve palsy ¹.
• Tissue loss: vascular compromise can cause tissue necrosis and rarely, vision loss ⁸.
• Action: stop injection, assess perfusion, initiate hyaluronidase protocol, and escalate urgently.

Skin Necrosis

Early skin change is a rescue opportunity; delayed recognition converts ischaemia into tissue loss.

• Warning pattern: pain out of proportion, mottling, grey-purple change, pustulation, or ulceration.
• Compression injury: excessive volume in a tight soft-tissue envelope can compromise perfusion.
• Hyaluronidase access: clinics performing HA NSR should have hyaluronidase immediately available ¹⁵.
• Early treatment: earlier recognition and treatment are associated with better outcomes and possible complete resolution ¹⁵.

Visual Symptoms

Any visual complaint during or after nasal injection is an emergency.

• Symptoms: blurred vision, field loss, diplopia, ocular pain, headache, ptosis, or ophthalmoplegia.
• Immediate response: stop injecting, call emergency ophthalmology, and activate local filler-embolus protocol.
• Counselling: rare major complications include infection, vascular compromise, skin necrosis, and blindness ¹⁶.
• Documentation: record timing, product, volume, site, symptoms, actions, and escalation contacts.

Infective and Inflammatory Events

Distinguish expected swelling from infection, delayed inflammatory oedema, and nodules requiring review.

• Infection: erythema, warmth, tenderness, pustules, fever, or progressive swelling need review.
• Delayed oedema: late swelling may reflect inflammatory reaction, product movement, or infection.
• Nodules: assess timing, tenderness, colour, and relationship to superficial product.

Aesthetic Problems

Most non-vascular failures are due to wrong indication, superficial placement, or excess volume.

• Asymmetry: reassess against baseline deviation before adding more filler.
• Overcorrection: dissolve or stage revision rather than layering further product.
• Tyndall effect: superficial HA may appear blue-grey, especially under thin dorsal skin.

Post-Procedural Care and Surveillance

Aftercare is not generic filler advice. The nose needs explicit vascular surveillance and a low threshold for urgent reassessment.

Immediate Observation

Do not discharge until skin colour, pain, and perfusion have been reassessed.

• Perfusion check: inspect capillary refill, blanching, livedo, dusky change, and focal tenderness.
• Vision screen: ask directly about visual blurring, diplopia, field change, or ocular pain.
• Documentation: record product, batch, total volume, sites, instrument, plane, and immediate findings.
• Rescue readiness: clinics offering HA NSR should be prepared to administer hyaluronidase for rare vascular compromise ⁴.

Patient Instructions

Give written instructions that separate expected swelling from red-flag symptoms.

• Expected symptoms: mild symptoms often subside in about 2 days and may be observed with supportive care when appropriate ¹.
• Avoid pressure: discourage rubbing, tight glasses, or manipulation until early tenderness settles.
• Red flags: escalating pain, blanching, mottling, ulceration, fever, pustules, or visual symptoms require urgent contact.
• No remote reassurance: photographic review may help triage, but vascular concerns need in-person assessment.

Early Review

Review early enough to detect vascular, infective, and contour problems before they mature.

• Follow-up timing: HA-filler NSR follow-up can include review at 21–30 days and at 1 year ⁵.
• Earlier review: bring patients back sooner for pain, colour change, swelling, asymmetry, or anxiety.
• Post-rhinoplasty timing: after surgical rhinoplasty, NSR should be delayed for at least 12 months in one review recommendation ³.
• Touch-up caution: avoid early additive correction while swelling or vascular uncertainty persists.

Escalation Pathway

Treat concerning nasal changes as time-sensitive until vascular compromise and infection are excluded.

• Necrosis or infection: suspected infection or skin necrosis warrants urgent antibiotics and steroid treatment with consideration of hyaluronidase ¹.
• HA complication: timely hyaluronidase use may improve outcomes when serious HA-related complications are suspected ¹.
• Delayed nodules: assess for inflammatory nodule, biofilm, superficial product, or delayed hypersensitivity.
• Thread concerns: persistent clots, visible threads, discomfort, or other concerns after nose-thread NSR should prompt review ¹⁷.

Outcomes and Counselling

The counselling standard is high because the procedure is elective, additive, and performed in a danger zone. Patients must understand what filler can improve and what only surgery can change.

Aesthetic Outcomes

Promise contour improvement, not a smaller, straighter, or structurally reconstructed nose.

• Achievable changes: radix height, dorsal smoothness, concavity camouflage, mild asymmetry, and modest projection.
• Unachievable changes: reduction, true narrowing, septal straightening, airway improvement, or major tip rotation.
• Satisfaction: HA NSR studies reviewed reported consistently high satisfaction ¹⁴.
• Secondary cases: one secondary liquid rhinoplasty series reported 92% patient-reported satisfaction ¹⁹.

Durability and Maintenance

Frame HA filler as a temporary treatment with planned maintenance rather than a one-off rhinoplasty substitute.

• Longevity: HA NSR effectiveness has been reported to last 8 to 14 months ¹¹.
• Repeat treatment: in one 2,130-patient ascending-technique series, 62% repeated NSR after one year ¹³.
• Reversibility: HA can be dissolved when contour, vascular, or inflammatory problems require it.
• Maintenance risk: repeated treatment can accumulate product and complicate later assessment.

Revision and Dissolution

Use revision only after identifying whether the problem is volume, placement, swelling, or wrong indication.

• Overfill: dissolution is safer than adding more product to a bulky or tense nose.
• Asymmetry: compare with baseline photographs before treating perceived new deviation.
• Dissatisfaction drivers: unrealistic goals, poor understanding of additive treatment, and unrecognised baseline asymmetry.
• Surgery later: prior filler can obscure planes, distort tissues, and affect surgical planning.

Risk Counselling

Severe complications are rare, but consent must treat them as real because consequences can be permanent.

• Severe events: large cohort data suggest severe complications after HA filler injection are rare, but risk-reduction measures remain necessary ¹⁸.
• Patient language: explain necrosis and blindness plainly, without minimising or catastrophising.
• Evidence limits: the HA NSR evidence base includes a systematic review of 3,928 patients across 23 articles, but better RCTs were still requested ¹⁴.
• Decision standard: proceed only when the expected contour benefit justifies the vascular risk in that individual nose.

References